These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12874006)

  • 41. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
    Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
    Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo.
    Noh YH; Matsuda K; Hong YK; Kunstfeld R; Riccardi L; Koch M; Oura H; Dadras SS; Streit M; Detmar M
    J Invest Dermatol; 2003 Dec; 121(6):1536-43. PubMed ID: 14675207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.
    Rivera-Fillat MP; Reig F; Martínez EM; Grau-Oliete MR
    J Pept Sci; 2010 Jul; 16(7):315-21. PubMed ID: 20552567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy.
    Streit M; Stephen AE; Hawighorst T; Matsuda K; Lange-Asschenfeldt B; Brown LF; Vacanti JP; Detmar M
    Cancer Res; 2002 Apr; 62(7):2004-12. PubMed ID: 11929817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.
    Dings RP; Yokoyama Y; Ramakrishnan S; Griffioen AW; Mayo KH
    Cancer Res; 2003 Jan; 63(2):382-5. PubMed ID: 12543791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of hypoxia in a preclinical model of tumor micrometastases.
    Simonsen TG; Gaustad JV; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):879-88. PubMed ID: 20159362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue.
    Rofstad EK; Ruud EB; Mathiesen B; Galappathi K
    Clin Cancer Res; 2010 Feb; 16(3):936-45. PubMed ID: 20103667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.
    Liu P; Wang Y; Li YH; Yang C; Zhou YL; Li B; Lu SH; Yang RC; Cai YL; Tobelem G; Caen J; Han ZC
    Leuk Res; 2003 Aug; 27(8):701-8. PubMed ID: 12801528
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts.
    Rofstad EK; Graff BA
    J Invest Dermatol; 2001 Nov; 117(5):1042-9. PubMed ID: 11710911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.
    Zhou J; Rothman VL; Sargiannidou I; Dimitrov S; Qiu C; Smith E; Sheffield J; Sharma M; Tuszynski GP
    J Cell Biochem; 2004 May; 92(1):125-46. PubMed ID: 15095410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
    Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
    Soffer SZ; Kim E; Moore JT; Huang J; Yokoi A; Manley C; O'Toole K; Middlesworth W; Stolar C; Yamashiro D; Kandel J
    J Pediatr Surg; 2001 Dec; 36(12):1781-4. PubMed ID: 11733906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
    Kozin SV; Winkler F; Garkavtsev I; Hicklin DJ; Jain RK; Boucher Y
    Cancer Res; 2007 Jun; 67(11):5076-82. PubMed ID: 17545583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
    Ooyama A; Oka T; Zhao HY; Yamamoto M; Akiyama S; Fukushima M
    Cancer Lett; 2008 Aug; 267(1):26-36. PubMed ID: 18420342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
    Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
    Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
    Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
    Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.